ResMed (RMD) Stock Price, News & Analysis

Company Overview

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $231.26 to $235.07
• 50-Day Range: $231.43 to $256.07
• 52-Week Range: $147.39 to $260.49
• Volume: 1.12 million shs
• Average Volume: 1.05 million shs
• Market Capitalization: $34.46 billion
• P/E Ratio: 31.10
• Dividend Yield: 0.90%
• Price Target: $225.70
• Consensus Rating: Moderate Buy

ResMed Stock Analysis - MarketRank™

ResMed scored higher than 95% of companies evaluated by MarketBeat, and ranked 80th out of 973 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ResMed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

ResMed has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.30%

Earnings Growth

Earnings for ResMed are expected to grow by 8.30% in the coming year, from $9.28 to $10.05 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ResMed is 31.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.19.

Price to Earnings Ratio vs. Sector

The P/E ratio of ResMed is 31.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.98.

Price to Earnings Growth Ratio

ResMed has a PEG Ratio of 1.71. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

ResMed has a P/B Ratio of 6.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.37% of the outstanding shares of ResMed have been sold short.

Short Interest Ratio / Days to Cover

ResMed has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in ResMed has recently decreased by 8.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

ResMed has a dividend yield of 0.90%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

ResMed has been increasing its dividend for 13 years.

Dividend Coverage

The dividend payout ratio of ResMed is 28.08%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, ResMed will have a dividend payout ratio of 21.09% next year. This indicates that ResMed will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -0.70

Percentage of Shares Shorted

5.37% of the outstanding shares of ResMed have been sold short.

Short Interest Ratio / Days to Cover

ResMed has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in ResMed has recently decreased by 8.89%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.01

News Sentiment

ResMed has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for ResMed this week, compared to 9 articles on an average week.

Search Interest

Only 4 people have searched for RMD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

5 people have added ResMed to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ResMed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,086,020.00 in company stock.

Percentage Held by Insiders

Only 0.71% of the stock of ResMed is held by insiders.

Percentage Held by Institutions

54.98% of the stock of ResMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RMD Stock Analysis - Frequently Asked Questions

How have RMD shares performed this year?

ResMed's stock was trading at $172.02 on January 1st, 2024. Since then, RMD shares have increased by 36.5% and is now trading at $234.77.
View the best growth stocks for 2024 here.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its quarterly earnings results on Thursday, October, 24th. The medical equipment provider reported $2.20 EPS for the quarter, beating the consensus estimate of $2.03 by $0.17. The company's revenue for the quarter was up 11.1% compared to the same quarter last year.
Read the conference call transcript.

Does ResMed have any subsidiaries?

The following companies are subsidiaries of ResMed: Propeller Health, and Matrixcare.

Who are ResMed's major shareholders?

ResMed's top institutional shareholders include State Street Corp (4.27%), Charles Schwab Investment Management Inc. (0.63%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.51%) and Congress Asset Management Co. (0.39%). Insiders that own company stock include Michael J Farrell, Robert Andrew Douglas, Brett Sandercock, David Pendarvis, Peter C Farrell, Kaushik Ghoshal, Justin Leong, Michael J Rider, Karen Drexler, Lucile Blaise, Witte Jan De, Carol Burt and James Hollingshead.
View institutional ownership trends.

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ResMed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Ex-Dividend for 9/19 Dividend: 8/15/2024
• Dividend Payable: 9/19/2024
• Last Earnings: 10/24/2024
• Ex-Dividend for 12/12 Dividend: 11/07/2024
• Today: 11/15/2024
• Dividend Payable: 12/12/2024
• Next Earnings (Estimated): 1/22/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:RMD
• CUSIP: 76115210
• CIK: 943819
• Web: www.resmed.com
• Phone: (858) 836-5000
• Fax: 858-836-5501
• Employees: 9,980
• Year Founded: 1989

Price Target and Rating

• Average Stock Price Target: $225.70
• High Stock Price Target: $283.00
• Low Stock Price Target: $180.00
• Potential Upside/Downside: -3.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 12 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $7.55
• Trailing P/E Ratio: 31.09
• Forward P/E Ratio: 25.30
• P/E Growth: 1.71
• Net Income: $1.02 billion
• Net Margins: 23.15%
• Pretax Margin: 28.62%
• Return on Equity: 25.53%
• Return on Assets: 17.59%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 2.92
• Quick Ratio: 1.91

Sales & Book Value

• Annual Sales: $4.69 billion
• Price / Sales: 7.36
• Cash Flow: $9.20 per share
• Price / Cash Flow: 25.52
• Book Value: $35.39 per share
• Price / Book: 6.63

Miscellaneous

• Outstanding Shares: 146,800,000
• Free Float: 145,754,000
• Market Cap: $34.46 billion
• Optionable: Optionable
• Beta: 0.69